It might have been the torrential rain that fell on the first day of the JP Morgan Annual Healthcare Conference that dampened the spirits of the 9,000 plus delegates attending the traditional annual kickoff for life sciences-focused companies, but the dearth of seismic announcements during the meeting cannot have helped. Major topics of discussion included perennial concerns around pricing models, lackluster deal announcements, poor gender and racial diversity, and what US companies might do with the anticipated tax windfall. There was a lot of discussion but not much clarity.
With the FDA approving the largest number of new molecular entities in more than a decade, there was much backslapping...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?